Live keynote: Antibody manufacturing strategies to address a pandemic

• The first antibody treatments for combatting COVID-19 infections will hopefully soon be making a vital and growing contribution to bringing the current global pandemic under control. The FDA is reviewing emergency use authorization requests from both Eli Lilly and Company and Regeneron
• The pandemic has challenged the biopharmaceutical industry to consider new ways to leverage antibody production capacity most effectively to meet the need for rapid early phase development and high-demand commercial manufacturing. Only by rising to these challenges can the industry get medicines to the largest number of patients in need, in the fastest possible time
• This presentation will discuss what has been learned so far during the pandemic and the impact it may have on manufacturing strategies for antibody therapeutics in the future

Nick Hutchinson, Business Steering Group Lead for Mammalian Cell Culture Services, FUJIFILM Diosynth Biotechnologies